CTLA4 and melanoma: Other studies demonstrated a correlation between the benefits of checkpoint blockade immunotherapy and the mutational burden in patients with melanoma and non-small cell lung cancer11–13, and showed that patients with tumours enriched for clonal neoantigens have increased sensitivity to anti-PD-1/anti-CTLA-4 immunotherapy14.